APRI_AST_to_platelet_ratio_index v.1
An index to determine the likelihood of hepatic fibrosis and cirrhosis in patients with chronic hepatitis C (CHC).
To record the parameter and to interpret the chance of fibrosis or cirrhosis in CHC patients.
APRI offers a non-invasive way to predict which patients have cirrhosis thus avoiding unnecessary liver biopsy. APRI is calculated based on the following formula: APRI = ((AST / AST Upper Limit of Normal) x 100) / Platelet count The measurement unit for AST and AST Upper Limit of Normal is IU/L and for platelet count is in 10^9/L. The interpretation is based on the 2011 meta-analysis in Hepatology by Lin et. al. Significant fibrosis: APRI threshold of 0.7 was 77% sensitive and 72% specific. Severe fibrosis: APRI threshold of 1.0 was 61% sensitive and 64% specific. APRI of >=2 was 36% sensitive and 93% specific. Cirrhosis: APRI threshold of 1.0 was 76% sensitive and 72% specific. APRI of >=2 was 46% sensitive and 91% specific.
Not intended to be used as a single method for determining the chance of fibrosis or cirrhosis in CHC patients.
1. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518-26. 2. Khan DA, Fatima Tuz Z, Khan FA, Mubarak A. Evaluation of diagnostic accuracy of APRI for prediction of fibrosis in hepatitis C patients. J Ayub Med Coll Abbottabad 2008; 20: 122-126. 3. Lin ZH, Xin YN, Dong QJ, et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology. 2011;53:726-36
OBSERVATION.lab_test-liver_function.v1, OBSERVATION.apri_ast_platelet_ratio_index.v0, OBSERVATION.lab_test-full_blood_count.v1, EVALUATION.apri_ast_platelet_ratio_index.v0
